Meeting
2021 ASCO Annual Meeting
Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*).
Presenter
Jennifer M. Specht, MD
University of Washington
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT04020575
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS2663)
DOI
10.1200/JCO.2021.39.15_suppl.TPS2663
Abstract #
TPS2663
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2020 ASCO Virtual Scientific Program
A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.
Speaker: Rodney Paul Rocconi, MD
Videos & Slides
2016 ASCO Annual Meeting
Target-based therapeutic matching of phase I trials in patients with advanced breast cancer (BC pts) in the Royal Marsden Hospital Drug Development Unit (RMH DDU).
Speaker: Brent O'Carrigan, MBBS, MMed, MRCP, FRACP
Speaker: Julie Vose, MD, MBA, FASCO
Speaker: Helen M. Parsons, PhD, MPH